Association of SLE damage with SLE myopathy
| Damage component | Myositis, n (%) | No myositis, n (%) | OR | P value | Adjusted OR | Adjusted p value |
| Cataract | 41 (23.2) | 374 (16.8) | 1.5 (1.04–2.16) | 0.0307 | 1.5 (1.04–2.18) | 0.0318 |
| Cognitive impairment | 19 (10.8) | 150 (6.7) | 1.69 (1.02–2.79) | 0.0422 | 1.87 (1.12–3.13) | 0.0166 |
| Seizure | 9 (5.1) | 102 (4.6) | 1.13 (0.56–2.27) | 0.7337 | 1.23 (0.61–2.5) | 0.5674 |
| Cranial or peripheral neuropathy | 21 (11.9) | 199 (8.9) | 1.39 (0.86–2.24) | 0.1784 | 1.42 (0.88–2.31) | 0.1527 |
| Transverse myelitis | 1 (0.6) | 17 (0.8) | 0.75 (0.1–5.64) | 0.7773 | 0.6 (0.08–4.59) | 0.6234 |
| Proteinuria | 16 (9.1) | 184 (8.2) | 1.11 (0.65–1.9) | 0.6912 | 0.93 (0.54–1.6) | 0.786 |
| Pulmonary hypertension | 16 (9.1) | 97 (4.3) | 2.21 (1.27–3.84) | 0.005 | 1.98 (1.13–3.47) | 0.0171 |
| Pulmonary fibrosis | 25 (14.2) | 154 (6.9) | 2.24 (1.42–3.53) | 0.0005 | 2.01 (1.27–3.18) | 0.003 |
| Cardiomyopathy | 9 (5.1) | 79 (3.5) | 1.47 (0.73–2.99) | 0.2827 | 1.24 (0.6–2.54) | 0.5613 |
| Muscular atrophy/weakness | 19 (10.7) | 45 (2) | 5.89 (3.37–10.32) | <0.0001 | 5.43 (3.05–9.66) | <0.0001 |
| Arthritis | 19 (10.7) | 130 (5.9) | 1.93 (1.16–3.2) | 0.0112 | 1.66 (0.99–2.78) | 0.0546 |
| Premature gonadal failure | 14 (8) | 100 (4.5) | 1.85 (1.03–3.3) | 0.039 | 1.9 (1.05–3.43) | 0.0346 |
| Diabetes | 26 (14.8) | 168 (7.5) | 2.13 (1.37–3.33) | 0.0009 | 1.92 (1.22–3.02) | 0.0048 |
| Hypertension | 79 (44.9) | 720 (32.4) | 1.7 (1.24–2.31) | 0.0008 | 1.45 (1.06–2) | 0.0212 |
P values <0.05 were considered statistically significant.